Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Muncie, IN
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Muncie, IN
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Columbia, MO
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
St Louis, MO
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Billings, MT
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Cherry Hill, NJ
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Hackensack, NJ
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Morristown, NJ
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Albuquerque, NM
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Bronx, NY
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Hudson, NY
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Hudson, NY
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Jamaica, NY
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Jamaica, NY
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
New York, NY
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Raleigh, NC
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Tulsa, OK
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Bend, OR
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Portland, OR
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Kingston, PA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Kingston, PA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Willow Grove, PA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Willow Grove, PA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Columbia, SC
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Memphis, TN
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Abilene, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Arlington, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Beaumont, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Bedford, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Denton, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Denton, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Flower Mound, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Flower Mound, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Garland, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Garland, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
McAllen, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Odessa, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Odessa, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Paris, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Paris, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Round Rock, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Sherman, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Sherman, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Sugar Land, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Temple, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
The Woodlands, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Tyler, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Waco, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Webster, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Wichita Falls, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Ogden, UT
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials